0HD2 logo

Alnylam Pharmaceuticals LSE:0HD2 Stock Report

Last Price

US$278.52

Market Cap

US$36.7b

7D

10.4%

1Y

83.1%

Updated

24 Mar, 2025

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

LSE:0HD2 Stock Report

Market Cap: US$36.7b

0HD2 Stock Overview

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. More details

0HD2 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 64.9% below our estimate of its fair value

Earnings are forecast to grow 58.08% per year

Earnings have grown 15.8% per year over the past 5 years

Risk Analysis

Significant insider selling over the past 3 months


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alnylam Pharmaceuticals, Inc. Competitors

Genus

LSE:GNS

UK£1.3b

Haleon

LSE:HLN

UK£35.5b

Oxford Biomedica

LSE:OXB

UK£322.7m

Avacta Group

AIM:AVCT

UK£149.9m

Price History & Performance

Summary of share price highs, lows and changes for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$278.52
52 Week HighUS$303.89
52 Week LowUS$142.05
Beta0.39
1 Month Change12.54%
3 Month Change14.36%
1 Year Change83.06%
3 Year Change71.30%
5 Year Change180.52%
Change since IPO107.25%

Recent News & Updates

Recent updates

Shareholder Returns

0HD2GB BiotechsGB Market
7D10.4%-1.4%-0.3%
1Y83.1%-11.1%6.5%

Return vs Industry: 0HD2 exceeded the UK Biotechs industry which returned -11.7% over the past year.

Return vs Market: 0HD2 exceeded the UK Market which returned 6.3% over the past year.

Price Volatility

Is 0HD2's price volatile compared to industry and market?
0HD2 volatility
0HD2 Average Weekly Movement6.1%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.9%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0HD2 has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0HD2's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,230Yvonne Greenstreetwww.alnylam.com

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
0HD2 fundamental statistics
Market capUS$36.68b
Earnings (TTM)-US$278.16m
Revenue (TTM)US$2.25b

16.3x

P/S Ratio

-131.9x

P/E Ratio

Is 0HD2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HD2 income statement (TTM)
RevenueUS$2.25b
Cost of RevenueUS$323.37m
Gross ProfitUS$1.92b
Other ExpensesUS$2.20b
Earnings-US$278.16m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.15
Gross Margin85.62%
Net Profit Margin-12.37%
Debt/Equity Ratio3,684.7%

How did 0HD2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 01:34
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 60 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg